In 2018, the US FDA formally approved the PD-1 antibody Keytruda in combination with chemotherapy as the first line of treatment for NSCLC, regardless of the level of PD-L1 expression in patients, excluding patients with EGFR mutations and ALK fusion (62). The gene discussed is CD274; the disease is non-small cell lung carcinoma.